

Wisconsin Department of Justice

Wisconsin Opioid Settlement Requirements

Laura E. McFarlane Deputy Unit Director Assistant Attorney General

Outline

- Background
- Approved Uses
- Reporting Obligations



Background

- Timeline
- State-Local MOUs
- Settlement Agreements
- Bankruptcies

Memorandums of Understanding

- Wisconsin Local Government Memorandum of Understanding
 Addendum to Wisconsin Local Government Memorandum of Understanding
- Wisconsin State-Local Government Memorandum of Understanding
 Distributors
 Janssen
- Wisconsin State-Local Government Memorandum of Understanding for the Allocation of Opioid Settlement Proceeds

Walgreens, Walmart, CVS, Teva, and Allergan
May apply to future settlements by election of Attorney General

 Wisconsin State-Local Government Opioid Bankruptcy Memorandum of Understanding

Settlement Agreements

Distributors

DHS	Local Govt.	Local Govt. Atty.	Total	
2022 \$ 13,614,112.63	\$ 16,006,139.57	\$ 4,001,534.89	\$ 33,621,787.09	
2023 \$ 7,371,692.89	\$ 8,201,887.96	\$ 2,050,471.99	\$ 17,624,052.84	

Janssen

DHS		Local (Govt. Lo	ocal Govt. Atty.	Total	
2022	\$ 17,090,	532.69 \$ 31,2	243,884.52 \$	7,810,971.13	\$ 56,145,388.35	
2023	\$ 617	,290.47			\$ 617,290.47	

Walgreens, Walmart, CVS, Teva, and Allergan

DHS	Local Govt.	Local Govt. Atty.	Total	
2024 [1] \$ 23,129,138.06	\$ 43,555,052.01	\$ 8,876,781.46	\$ 75,560,971.53	

Bankruptcies

Mallinckrodt

DHS		Local Govt.	Total	
2023	\$1,756,497.80	\$4,098,494.87	\$5,854,992.67	

Endo

Purdue

Approved Uses

Amounts allowed on Non-Approved Uses

Distributors	15%
Janssen	13.50%
Teva	15%
Allergan	15%
Walmart	15%
Walgreens	5%
CVS	4.5%
Mallinckrodt	0%

Payment #/Year	Suspension Applies to:	Atty Fee, Costs & Additional Restitution Amount	Base	Incentives A, B & C (maximum)	Incentive D (Lookback Payment)	Credit	Total
Payment 1 ED+90 days	None	\$103,244,576	\$282,175,271		-	\$14,580,153	\$400,000,000
Payment 2 July 2022	None		\$658,320,615				\$658,320,615

Approved Uses

EXHIBIT E

List of Opioid Remediation Uses

Schedule A Core Strategies

States and Qualifying Block Grantees shall choose from among the abatement strategies listed in Schedule B. However, priority shall be given to the following core abatement strategies ("Core Strategies"). 14

A. NALOXONE OR OTHER FDA-APPROVED DRUG TO REVERSE OPIOID OVERDOSES

- Expand training for first responders, schools, community support groups and families; and
- Increase distribution to individuals who are uninsured or whose insurance does not cover the needed service.

B. MEDICATION-ASSISTED TREATMENT ("MAT") DISTRIBUTION AND OTHER OPIOID-RELATED TREATMENT

 Increase distribution of MAT to individuals who are uninsured or whose insurance does not cover the needed service;

Reporting Requirements

- Distributors and Janssen
 - Every six months, ending 6/30 and 12/31, report due on Non-Opioid Remediation Uses
 - In 2022, Local Governments reported:
 - \$3,689,596.45 on Non-Approved Uses for Distributors
 - \$7,083,512.92 on Non-Approved Uses for Janssen
 - In 2022, Local Governments have not reported any Non-Approved Uses
 - Deadline is March 31, 2024 to report on 7/1/2023-12/31/2023 Non-Approved Uses
- Mallinckrodt
 - Each year every beneficiary is required to report on abatement uses
- Walgreens, Walmart, CVS, Teva, and Allergan
- MOUs
- Wis. Stat. § 165.12(4)(c)
 - By May 1 annually, a local government that receives money from an opioid settlement shall submit a report to the DOJ and JCF that includes (1) the amount of money in the local government's segregated account as of December 31 of the previous year and (2) an accounting of the receipts and disbursements from the segregated account in the previous year.

(1) Amounts from Settlement Fund used for purposes that do not qualify as Opioid Remediation	\$ 7,083,512.92
(2) Portion of amount in clause (1) used for attorneys'	
fees, investigation costs, litigation costs, or costs	\$ 7,083,512.92
related to the operation and enforcement of the	ψ 1,000,012.2
Settlement Agreement	



Thank You!